Core Viewpoint - SAILUN Biotech (688163.SH) reported a slight increase in revenue and net profit for the first three quarters of 2025, indicating stable growth in its financial performance [1] Financial Performance - The total operating revenue for the first three quarters reached 175 million yuan, representing a year-on-year growth of 1.07% [1] - The net profit attributable to shareholders was 64.21 million yuan, showing a year-on-year increase of 2.01% [1] - The basic earnings per share stood at 0.59 yuan [1]

Financial Performance - The company's revenue for Q3 2025 was ¥74,319,211.31, a decrease of 1.22% compared to the same period last year[3] - The total profit for the period was ¥37,052,211.73, reflecting an increase of 1.30% year-over-year[3] - The net profit attributable to shareholders was ¥31,233,921.44, up by 1.94% from the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥27,908,599.12, which increased by 1.43% compared to the same period last year[3] - The basic earnings per share for the quarter was ¥0.29, with a year-to-date figure of ¥0.59, reflecting a 1.72% increase[4] - Total operating revenue for the first three quarters of 2025 reached RMB 175,138,574.09, a slight increase from RMB 173,291,573.09 in the same period of 2024, representing a growth of approximately 1.06%[17] - Net profit for the first three quarters of 2025 was RMB 64,210,654.81, compared to RMB 62,947,540.75 in 2024, indicating an increase of approximately 2.00%[19] - The company’s total profit for the first three quarters of 2025 was RMB 74,817,469.40, compared to RMB 73,631,451.78 in 2024, reflecting an increase of approximately 1.61%[19] Assets and Liabilities - Total assets at the end of the period were ¥1,161,534,035.34, representing a 3.71% increase from the end of the previous year[4] - The company's total liabilities rose to CNY 36,453,171.78 from CNY 24,533,348.17, reflecting an increase in financial obligations[14] - The total equity attributable to shareholders increased to CNY 1,125,080,863.56 from CNY 1,095,500,608.75, showing growth in shareholder value[14] - The company's accounts receivable increased to CNY 65,179,876.60 from CNY 36,678,957.69, indicating improved sales performance[12] - The fixed assets increased to CNY 114,577,515.78 from CNY 108,979,777.03, suggesting ongoing investment in infrastructure[13] - The company reported a total non-current asset of CNY 244,024,044.52, up from CNY 203,671,011.22, reflecting long-term investment growth[13] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of ¥38,166,287.22, which decreased by 6.89% year-to-date[3] - The company's cash and cash equivalents decreased to CNY 74,948,031.35 from CNY 182,107,137.22, indicating a significant reduction in liquidity[12] - Cash flow from operating activities generated a net amount of RMB 38,166,287.22 in 2025, down from RMB 40,989,386.86 in 2024, a decrease of about 6.93%[21] - Cash flow from investing activities resulted in a net outflow of RMB 110,427,075.57 in 2025, contrasting with a net inflow of RMB 53,086,071.07 in 2024[22] - Cash and cash equivalents at the end of the third quarter of 2025 totaled RMB 74,948,031.35, a decrease from RMB 210,364,165.68 at the end of the same period in 2024[23] Research and Development - Research and development expenses totaled ¥4,402,191.05, accounting for 5.92% of revenue, an increase of 0.91 percentage points[4] - The company incurred research and development expenses of RMB 12,878,600.46 in 2025, down from RMB 16,170,774.43 in 2024, a decrease of about 20.00%[18] Non-Recurring Items - Non-recurring gains and losses for the period amounted to ¥3,325,322.32, with a year-to-date total of ¥7,774,982.99[7] - The company reported other income of RMB 497,430.05 in 2025, significantly lower than RMB 3,549,290.77 in 2024, indicating a decline of approximately 86.00%[18] Inventory and Current Assets - The total current assets slightly increased to CNY 917,509,990.82 compared to CNY 916,362,945.70 in the previous period[12] - The company's inventory decreased to CNY 38,759,460.00 from CNY 43,275,462.94, which may indicate improved inventory management[12] Operating Costs - Total operating costs decreased to RMB 105,193,973.75 in 2025 from RMB 107,900,485.01 in 2024, reflecting a reduction of about 2.52%[18]

Core Viewpoint - The company reported a slight decline in revenue for the third quarter, while net profit showed a modest increase, indicating mixed performance in the latest financial results [1] Financial Performance - Q3 revenue was 74.3192 million yuan, a year-on-year decrease of 1.22% [1] - Q3 net profit was 31.2339 million yuan, a year-on-year increase of 1.94% [1] - Revenue for the first three quarters was 175 million yuan, a year-on-year increase of 1.07% [1] - Net profit for the first three quarters was 64.2107 million yuan, a year-on-year increase of 2.01% [1]

Group 1 - On September 25, 2023, Siron Biotech experienced a decline of 0.99% with a trading volume of 17.9856 million yuan [1] - The financing data for Siron Biotech on the same day showed a financing purchase amount of 1.4958 million yuan and a financing repayment of 2.0808 million yuan, resulting in a net financing buy of -0.5850 million yuan [1] - As of September 25, 2023, the total balance of margin trading for Siron Biotech was 155 million yuan, with the financing balance accounting for 6.19% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, 2023, the number of shareholders for Siron Biotech was 7,724, an increase of 9.39% from the previous period, while the average circulating shares per person decreased by 8.58% to 5,744 shares [2] - For the first half of 2023, Siron Biotech reported an operating income of 101 million yuan, representing a year-on-year growth of 2.82%, and a net profit attributable to shareholders of 32.9767 million yuan, up 2.07% year-on-year [2] - Since its A-share listing, Siron Biotech has distributed a total of 248 million yuan in dividends, with 150 million yuan distributed over the past three years [2]

Group 1 - The company, Sairun Biotech (688163.SH), has stated that it currently has no plans to export its anti-snake venom serum [1]

Core Viewpoint - The company announced a cash dividend distribution of CNY 0.12 per share for the first half of 2025, totaling CNY 12,986,400 [2][4]. Distribution Plan - The profit distribution plan was authorized by the shareholders' meeting on May 16, 2025, and approved by the board meeting on August 25, 2025 [2][3]. - The distribution is based on a total share capital of 108,220,000 shares [4]. - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [3]. Implementation Details - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited [5]. - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the designated trading is completed [5]. Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of CNY 0.12 per share [9]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution; tax will be calculated upon the transfer of shares [9]. - For Qualified Foreign Institutional Investors (QFII), a 10% withholding tax will apply, resulting in a net distribution of CNY 0.108 per share [10]. - Hong Kong investors will also receive a net distribution of CNY 0.108 per share after a 10% withholding tax [11]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's board secretary office at 021-64959122 [12].

Group 1 - The company announced a cash dividend of 0.12 yuan per share (including tax) for the first half of 2025 [2] - The record date for the dividend is set for September 25, 2025 [2] - The ex-dividend date and the date of cash dividend distribution are both scheduled for September 26, 2025 [2]

证券代码：688163 证券简称：赛伦生物 公告编号：2025-027 上海赛伦生物技术股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/25 | 2025/9/26 | 2025/9/26 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东会授权董事会制 定，并经公司 2025 年 8 月 25 日召开的第四届董事会第八次会议审议通过后实施。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本108,220,000股为基数，每股派发现 金红利0.12元（含税），共 ...

Summary of Key Points Core Viewpoint - On September 11, a total of 9 companies had their restricted shares unlocked, with a total unlock volume of 114 million shares, amounting to a market value of 3.989 billion yuan based on the latest closing price [1]. Group 1: Unlock Volume - Two companies had unlock volumes exceeding 10 million shares: Sailun Biotech with 63.848 million shares and Qingmu Technology with 16.8263 million shares [1]. - The third company with significant unlock volume is Shida Group, which had 9.425 million shares unlocked [1]. Group 2: Unlock Market Value - Two companies had unlock market values exceeding 100 million yuan: Sailun Biotech with 1.567 billion yuan and Qingmu Technology with 1.119 billion yuan [1]. - The third company with a notable unlock market value is Huihan Co., which had an unlock market value of 685 million yuan [1]. Group 3: Unlock Ratio - Two companies had unlock ratios exceeding 10%: Sailun Biotech with 59.0% and Qingmu Technology with 18.18% [1]. - The third company with a significant unlock ratio is Haisheng Pharmaceutical, which had an unlock ratio of 7.38% [1].

Group 1 - The company has initiated two new drug research projects in the first half of 2025, focusing on broad-spectrum anti-snake venom antibodies and recombinant snake venom coagulase, currently in the laboratory research phase [1] - The company's export of anti-snake venom serum raw liquid to South Korea is noted, with both the export business amount and its proportion in operating revenue being very small [1] - Specific data regarding overseas operating revenue can be referenced in the company's annual reports [1]